Skip Navigation LinksHome > February 2004 - Volume 100 - Issue 2 > Cerebral Sinus Thrombosis in a Trauma Patient after Recombin...
Case Reports

Cerebral Sinus Thrombosis in a Trauma Patient after Recombinant Activated Factor VII Infusion

Siegel, Leonie J. M.D.*; Gerigk, Lars M.D.†; Tuettenberg, Jochen M.D.‡; Dempfle, Carl-Erik M.D.§; Scharf, Johann M.D.†; Fiedler, Fritz M.D.*

Free Access
Article Outline
Collapse Box

Author Information

SEVERAL investigators have reported the astonishing effect of recombinant activated factor VII (rFVIIa) in trauma patients with diffuse bleeding. Currently, rFVIIa is approved for the treatment of patients with hemophilia with inhibitors to factors VIII and IX. Conditions with increased thromboembolic risk, including trauma, extensive tissue damage, sepsis, arteriosclerosis, and disseminated intravascular coagulation, may be considered contraindications for the drug. Thrombotic complications in trauma patients are rarely observed. To our knowledge, this is the first report of a patient who experienced a cerebral sinus thrombosis in the posttraumatic period after rFVIIa administration.
Back to Top | Article Outline

Case Report

A 19-yr-old man was involved in a frontal motorbike accident. He had an open shaft fracture of the femur, pneumothorax, and lung contusions. A small frontal brain contusion was only visible on a follow-up computed tomographic (CT) scan, without any initial neurologic impairment.
After the pneumothorax was sufficiently drained, the patient underwent surgical reposition of his thigh. Stabilization was achieved with external skeletal fixation. The intense bleeding was under control after reposition and intermittent tamponade. No damage of major vessels was found. An extensive supracondylar hematoma was drained.
Twelve hours after stabilization of the fracture, the patient showed signs of bleeding. Before and during surgical revision of the thigh, he received 16 units of erythrocytes, 11 fresh frozen plasmas, 8 single-donor platelet concentrates, and a single bolus dose of 240 KU (60 μg/kg body weight) rFVIIa. Again, no damage of major vessels was found. Bleeding stopped promptly after administration of rFVIIa. During the operation, an intramuscular hematoma was drained, and fasciotomy was performed on the thigh and lower leg. After this, the patient was stable, with a hemoglobin concentration at 7.5–8 mg/dl.
Fig. 1
Fig. 1
Image Tools
Because of the patient’s pulmonary impairment, it was difficult to wean him off the respirator. After return to spontaneous ventilation, he showed changing levels of consciousness. A follow-up CT scan of the brain was performed at day 5, which showed a small frontal contusion without any space-occupying character (fig. 1A).
In the second week, the patient started to present signs of infection of the fracture site. His body temperature peaked on day 13 up to 39.7°C and decreased immediately after surgical revision and débridement. The leukocyte count at that time was 15.1 × 109/l, and C-reactive protein, with a maximum of 236 mg/l on day 9, had decreased to 100 mg/l on day 15. Reactive thrombocytosis occurred, with a maximum of 1,080 × 109/l on day 19.
On day 15, the patient presented with a unilateral dilated pupil with remaining prompt reaction to light, spontaneous inward rotation, extensions of the upper and lower limbs, and vomiting despite drained gastric tube. Native and contrast-enhanced CT scans were performed to rule out septic dissemination and did not show any pathologic findings (fig. 1B). Bacterial meningoencephalitis was ruled out by lumbar puncture. A possible systemic herpes simplex infection after the labial lesions was treated prophylactically with acyclovir until viral genome testing results were found to be negative by polymerase chain reaction.
After another 12 h, the patient again showed signs of impaired brainstem function. A second CT scan showed slightly dilated lateral ventricles. After the insertion of ventricular drainage, intracranial pressure did not increase.
Fig. 2
Fig. 2
Image Tools
Because of the persistent impaired consciousness, another follow-up CT scan was performed on day 21, and hypodense areas in the anterior parts of both thalami were found (fig. 1C). Bilateral thalamic edema after thrombosis of internal cerebral veins was considered to be the most likely diagnosis, but to visualize the thrombus and to rule out other causes of thalamic hypodensities, such as ischemic infarction, a magnetic resonance imaging study was performed on the same day. The corresponding areas of both thalami showed signs of edema (figs. 2A–C) but no contrast enhancement. Signal intensity in diffusion-weighted imaging was slightly increased, probably because of T2 sensitivity of the sequence, but not to the extent typically seen in ischemic infarction. There were no signs of intracerebral hemorrhage.
Fig. 3
Fig. 3
Image Tools
The thrombus itself was found in the proximal part of the straight sinus, obstructing the confluence of the inferior sagittal sinus and the great cerebral vein of Galen. It was surrounded by a narrow stripe of contrast media (fig. 3A). Phase contrast magnetic resonance angiography showed a remaining flow signal in the area of the thrombus (fig. 3B).
To achieve differentiation of the thrombus against a venous anomaly, conventional angiography was performed on the following day. In late venous images, sustained contrast was detected in the great cerebral vein of Galen, the internal cerebral veins, and the thalamostriate veins (fig. 3C), making venous congestion the most probable cause for thalamic edema.
Intravenous anticoagulant therapy was initiated, and within 3 weeks, the neurologic situation improved gradually (figs. 2B and C).
Back to Top | Article Outline


In several case reports 1,2 and small studies, 3 antihemorrhagic effects of recombinant activated factor VII (rFVIIa) has been described in diffuse hemorrhage of trauma and surgical patients. Massive transfusion dilutes coagulation factors and impairs platelet number and function. Excessive treatment with fluids such as hydroxyethyl starch preparations might directly compromise coagulation. Concomitant hypothermia causes slowing of enzymatic activities of the coagulation cascade and dysfunction of platelets. Release of procoagulant substances from ruptured tissues leads to a complex consumptive coagulopathy with enhanced fibrinolysis. Metabolic abnormalities, such as acidosis and hypocalcemia, further deteriorate coagulation.
Under these circumstances, diffuse bleeding often persists, despite apparently adequate surgical procedures and treatment with blood products and conventional hemostatic agents. In single cases 1 and small study groups, 2 rFVIIa was successfully given to achieve hemostasis in severe bleeding, without previous coagulopathy. Thromboembolic complications have been described, such as venous thrombosis, 4 myocardial infarction, 5 and disseminated intravascular coagulation. 6,7 The described thrombotic events often have occurred in the context of preexisting risk factors, e.g., crush injury, tissue necrosis, septicemia, atherosclerosis, or previous administration of activated prothrombin complex, making it difficult to pinpoint the contribution of rFVIIa to these adverse events.
In our patient, obvious clinical signs of his cerebral sinus thrombosis became evident 14 days after administration of rFVIIa, when the patient presented with a unilateral dilated pupil and spontaneous inward rotation. With a half-life of rFVIIa of approximately 6 h, a direct relation seems rather unlikely. However, because cerebral sinus thrombosis in the age group of our patient and with the presented trauma pattern is rare and extensive clinical experience with rFVIIa is lacking, we are considering a relation to the administration of rFVIIa, in contribution with an endothelial lesion of the cerebral sinus caused by the mild brain injury. With the exposure of subendothelium after the small blood vessel injury, cell-bound tissue factor may be exposed and may cause formation of microthrombus. Without enhancement of the coagulation by rFVIIa, the microthrombus might have resolved quickly, without any clinical recognition. With the administration of rFVIIa and the generation of a high thrombin burst, a more stable clot was probably created, not resolving until day 14 when, under septic conditions, the coagulation became activated. When toward day 14 the patient’s septic situation aggravated, the thrombus may have increased in volume, or smaller thrombi may have occluded the remaining drainage beside the initial thrombus, compromising the venous drainage of the thalamic region.
A similar delay between rFVIIa administration and thrombosis formation was seen by Van der Planken et al.4 in a hemophilia A patient with inhibitors and severe infectious disease. This patient experienced a distal deep venous thrombosis 18 days after rFVIIa transfusion. Also, d’Oiron et al.6 described a pulmonary embolism of the lung 5 days after discontinuation of rFVIIa infusion.
Despite the promising beneficial effect of rFVIIa for hemostasis in massively bleeding trauma patients, the thrombotic risk of the drug must be kept in mind. Therefore, close monitoring is necessary for early identification of thrombotic complications.
Back to Top | Article Outline


1. O’Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, Essex DW, Catanese CA, Strauss RA: Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400–5

2. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431–9

3. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201–5

4. Van der Planken MG, Schroyens W, Vertessen F, Michieles JJ, Berneman ZN: Distal deep venous thrombosis in a hemophilia A patient with severe infectious disease, 18 days after recombinant activated factor transfusion. Blood Coagul Fibrinolysis 2002; 13: 367–70

5. Peerlinck K, Vermylen J: Acute myocardial infarction following administration of recombinant activated factor VII in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775–6

6. d’Oiron R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Negrier C: Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644–7

7. Hedner U, Glazer S, Falch J: Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78–83

Cited By:

This article has been cited 21 time(s).

British Journal of Anaesthesia
Is recombinant FVIIa the magic bullet in the treatment of major bleeding?
Spahn, DR; Tucci, MA; Makris, M
British Journal of Anaesthesia, 94(5): 553-555.
Annales Francaises D Anesthesie Et De Reanimation
Use of activated recombinant FVII in the control of haemorrhage following trauma
Perrier, V; Morel, N; Bernard, JC; Julliac, B; Dewitte, A; Pouquet, O; Sztark, F; Dabadie, P
Annales Francaises D Anesthesie Et De Reanimation, 25(9): 990-993.
Journal of Clinical Anesthesia
The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications
Yusim, Y; Peret, A; Berkenstadt, H; Attia, M; Knoller, N; Sidi, A
Journal of Clinical Anesthesia, 18(7): 545-551.
Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom
Morris, S; Ridley, S; Munro, V; Christensen, MC
Anaesthesia, 62(1): 43-52.
European Journal of Trauma and Emergency Surgery
Cost-effectiveness of recombinant activated factor VII as adjunctive therapy for bleeding control in severely injured trauma patients in Germany
Rossaint, R; Christensen, MC; Choong, PIT; Boffard, KD; Riou, B; Rizoli, S; Kluger, Y; Lefering, R; Morris, S
European Journal of Trauma and Emergency Surgery, 33(5): 528-538.
Journal of Cardiothoracic and Vascular Anesthesia
The use of recombinant-activated factor VII to successfully control postoperative critical bleeding after emergency repair of ruptured abdominal aortic aneurysm in a noncoagulopathic patient
Dell'Utri, D; Passariello, M
Journal of Cardiothoracic and Vascular Anesthesia, 20(4): 570-572.
American Journal of Surgery
Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage
Khan, AZ; Parry, JM; Crowley, WF; McAllen, K; Davis, AT; Bonnell, BW; Hoogeboom, JE
American Journal of Surgery, 189(3): 331-334.
Anaesthesia and Intensive Care
Use of recombinant activated factor VII after axillofemoral bypass grafting
Cheng, CAY; Ho, AMH
Anaesthesia and Intensive Care, 34(3): 375-378.

International Journal of Obstetric Anesthesia
Recombinant factor VIIa in massive postpartum haemorrhage
Karalapillai, D; Popham, P
International Journal of Obstetric Anesthesia, 16(1): 29-34.
Archives of Surgery
Efficacy and safety of recombinant activated factor VII in major surgical procedures
Ranucci, M; Isgro, G; Soro, G; Conti, D; De Toffol, B
Archives of Surgery, 143(3): 296-304.

British Journal of Anaesthesia
Probable right atrial thrombus immediately after recombinant activated factor VII administration
Pang, G; Donaldson, A
British Journal of Anaesthesia, 99(2): 221-225.
Journal of the American College of Surgeons
Use of Recombinant Factor VIIa to Facilitate Organ Donation in Trauma Patients with Devastating Neurologic Injury
Stein, DM; Dutton, RP; Alexander, C; Miller, J; Scalea, TM
Journal of the American College of Surgeons, 208(1): 120-125.
Annales Francaises D Anesthesie Et De Reanimation
Recombinant activated factor VII as a life-saving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management
Brice, A; Hilbert, U; Roger-Christoph, S; Fernandez, H; Dumenil, AS; Descorps-Declere, A; Mercier, F; Benhamou, D
Annales Francaises D Anesthesie Et De Reanimation, 23(): 1084-1088.
Surgical Neurology
The use of recombinant activated factor VII in neurosurgery
Kapapa, T; Konig, K; Heissler, HE; Schatzmann, C; Tschan, CA; Perl, M; von Depka, M; Zumkeller, M; Rickels, E
Surgical Neurology, 71(2): 172-179.
Current Drug Targets
Uncontrolled Bleeding in Surgical Patients: The Role of Recombinant Activated Factor VIIa
Phillips, LE; Zatta, AJ; Schembri, NL; Noone, AK; Isbister, J
Current Drug Targets, 10(8): 744-770.

Annales Francaises D Anesthesie Et De Reanimation
rFVIIa administration in patient with a left ventricular assistance patient
Tual, L; Kirsch, M; Servant, JM; Drouet, L; Dhonneur, G
Annales Francaises D Anesthesie Et De Reanimation, 25(1): 29-32.
Journal of Emergency Nursing
Recombinant factor VIIa and the trauma patient
Criddle, LM
Journal of Emergency Nursing, 32(5): 404-408.
Recombinant factor VIIA in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial
Narayan, RK; Maas, AIR; Marshall, LF; Servadei, F; Skolnick, BE; Tillinger, MN
Neurosurgery, 62(4): 776-786.
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie
FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases
Pavese, P; Bonadona, A; Beaubien, J; Labrecque, P; Pernod, G; Letoublon, C; Barnoud, D
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie, 52(1): 26-29.

Critical Care
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: Post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
Kluger, Y; Riou, B; Rossaint, R; Rizoli, SB; Boffard, KD; Choong, PIT; Warren, B; Tillinger, M
Critical Care, 11(4): -.
European Journal of Anaesthesiology (EJA)
Use of recombinant factor VIIa for major haemorrhage
Pugh, RJ; Wenstone, R; Martlew, VJ; Marx, G
European Journal of Anaesthesiology (EJA), 22(7): 548-550.
PDF (176) | CrossRef
Back to Top | Article Outline

© 2004 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.

Article Tools